We expected that if LCN2 were an important anorexigenic factor, LCN2 deficiency during celastrol treatment should at least blunt celastrol’s appetite suppressing and anti-obesity effect at some level. The gene discussed is LCN2; the disease is obesity due to melanocortin 4 receptor deficiency.